Life Sciences Archive » July, 2018

Life Sciences - July, 2018

320 articles

• Janssen Loses Remicade Patent Case To Pfizer, Celltrion
• Monsanto Expert Rips Studies Linking Herbicide To Cancer
• OvaScience Can't Escape Investor IVF Treatment Suit
• Insys Founder Tries To Exit Suit Over Drug-Related Death
• Allergan Says Imprimis' Bad Faith Discovery Merits Sanctions
• ​​​​​​​FDA Warning Wire: Um, Don't Make Medicines In Kitchen Pots
• PTAB Must Redo Suboxone Patent Reviews Post-SAS
• Merck Says Vaccine Bundles Caused Low Prices, Not Harm
• Trends And Predictions For Serial Biologic Drug IPR Petitions
• Pharma Co. Duped Investors In $61M Offering, Suit Says
• Lawyers Compete To Represent Zetia Buyers In Antitrust Case
• Ex-Biotech CEO A 'Total Moron' But No Crook, NY Jury Hears
• Jury Awards Hologic $5M For NovaSure Patent Infringement
• FDA Rejects Insys Painkiller Spray Over Safety Concerns
• PTAB Nixes CardioNet Unit's Heart Monitor Patent
• Israeli Pharma Co. To Pay $2M To End Stock-Drop Suit
• FDA Sounds Alarm Over 'Vaginal Rejuvenation' Treatments
• Morgan Lewis Nabs 7-Partner IP Team From McDermott
• For Self-Driving Car Makers, Industry Standards Matter
• Law360 Names Top Attorneys Under 40
• Pomerantz Named Lead Counsel In Antares Pharma Fraud Suit
• Individualized Claims Thwart Testosterone RICO MDL
• Monsanto Herbicide's Link To Cancer Sound, Jury Told
• Ex-Insys Execs Say Feds' Bid To Redo RICO Case Is Futile
• Tibet Pharma Investors Escape Dismissal For Now In IPO Row
• Anthem, Express Scripts Were Fiduciaries, 2nd Circ. Hears
• Sandoz Holds Back On Cataract Drug Generic, Ending IP Suit
• GOP Lawmakers Seek FTC Scrutiny Of Drug Benefit Managers
• Czechs Say Dutch Ruling Backs $374M Award's Dismissal
• J&J Unit Can't Skip To En Banc Hearing In Pa. Mesh Appeal
• FTC Says Drugmakers Must Face AndroGel Antitrust Suit
• Innovator Liability Flunks The Dormant Commerce Clause
• AbbVie Investors Sue Over 1-Day $100M Stock Drop
• Fed. Circ. Nixes USPTO Bid For Win-Or-Lose Attys' Fees
• Monsanto's Toxicology Figures Don't Hold Up, Jury Hears
• Drugmaker Put 'Misbranded' Medicines On Market, Feds Say
• AstraZeneca Sues Over Generic Breast Cancer Drug
• J&J Can't Get New Judge For Philly Pelvic Mesh Trial
• E-Commerce Co. Pinduoduo Leads 7 IPOs Totaling $2.7B
• Warning Claims Axed In Bard Blood Vessel Filter Bellwether
• Judge Slams 'Stupid Argument' In Bid To DQ Shkreli Attys
• UK Tribunal Won't Pause Epilepsy Drug Case For Appeals
• Media Can't Access Drug Co. Data In Opioid MDL
• What You Need To Know About Trump's EU Trade Epiphany
• King & Spalding Nabs IP Partner From Paul Hastings
• Shkreli Atty Deserves At Least 5 Years In Prison, Feds Say
• Bristol-Myers Unlikely To Shake Up Class Action Landscape
• The Future Of Authenticating Audio And Video Evidence
• Pharma Statisticians Say Insider Trading Trial Was Tainted
• House Votes To Extend Exemption From ACA Insurer Fee
• Clint Eastwood Sues Medical Co. For Patent Investments
• Gene Editing Co. Bluebird Bio Offers 3.4M Shares At $162
• Discovery War Breaks Out In Opioid MDL Bellwethers
• Novo Nordisk Says Execs Didn't Hide Insulin Sales Woes
• EU, US Making A Bid To Cool Rising Trade Tensions
• USCIS Policy Changes Put STEM Students On Shaky Footing
• Fenwick-Led Bloom Energy Leads 2 IPOs Raising $337.5M
• Boston Scientific Chips Away At Nevro Patents, Beats IP Suit
• Wis. Tribe Reaches Deal With State Over Hemp Program
• From Billable Hours To Bedtime Stories: Lawyering With Children
• Calif. Rules For Advising Cannabis Clients Need Clarity: Part 2
• Must Whole Patent Be Nixed To Forfeit 180-Day Exclusivity?
• Minn. Tribe Sues Drugmakers, Distributors Over Opioid Crisis
• Feds Try To Clear Up Ex-Insys Execs' RICO Charge For Judge
• 2nd Circ. Nixes Class Cert. In J&J 'Natural' Baby Wash Suit
• Bitter Dissent Shreds Rehearing Denial In Md. Drug Price Row
• How Mammoth Student Loans Are Dogging Today's Lawyers
• FDA To Mull New Ideas On Biosimilar Competition, Approvals
• New Risks For US Cos. Inadvertently Supporting North Korea
• Calif. Rules For Advising Cannabis Clients Need Clarity: Part 1
• Reed Smith Adds Norton Rose Health Care Privacy Pro
• A Clever Scheme To Protect Invalid Patents Has Failed
• Law360's Global 20 Doesn't Acknowledge Global Networks
• Grant & Eisenhofer Not Entitled To $31M Fee, Ex-Client Says
• Monsanto's Herbicide Caused Open Lesions, Jury Hears
• Bayer Can't Keep 16 Suits Over Essure Injuries In Fed. Court
• I-MAK Strikes Out In Final Gilead Hep C Patent Challenge
• Perkins Coie Nabs Dorsey & Whitney VC Pro In Silicon Valley
• Fed. Circ. Tribal Ruling Puts State PTAB Immunity In Doubt
• FTC To Seek Revival Of Parts Of AbbVie Suit After $448M Win
• Fed. Circ. Prior Art Ruling Illegal, Ariosa Tells Justices
• Time For Sunshine On 3rd-Party Litigation Funding
• BioChemics Wants More Time To Come Up With SEC's $17M
• Theranos Settles Indirect Investors' Fraud Suit
• Is The Grass Greener On The Solo Side?
• 1st Circ. Wonders Why FDA Should Not Decide Eyedrop Suit
• Real Estate Brokerage Leads 4 IPO Launches Exceeding $1.2B
• NJ Justices Won't Review Toss Of $25M Accutane Verdict
• China's New Medical Device Regulations Bring Big Changes
• Law360's Satisfaction Survey: By The Numbers
• The Least-Stressed Attorneys In A Stressed-Out Profession
• Acadia Hit With Securities Suit Over Drug Linked To Deaths
• Oncologist Says Roundup Caused Groundskeeper's Cancer
• Pharma Co. Can Peek At Just 1 Email In Cancer Research Suit
• Greenberg Traurig Adds Former Teva Atty To Philly Office
• 11 Firms To Steer IPOs Topping $3B In Busy Summer Stretch
• J&J Faces Bid To Revive Cancer Victim's $417M Talc Win
• Endo, Mallinckrodt Target Drug Dealers With Opioid Suit
• Keryx Trims, But Can't Scrap Shareholder Stock-Drop Suit
• Ariosa Can't Shake $27M Verdict In Illumina Prenatal IP Row
• Faulty Expert Opinion Tanks Auxilium Testosterone Suit
• Morgan Lewis-Guided Biotech Firm Scores $101.5M From IPO
• Full Fed. Circ. Should Nix UCB's Vimpat Patent, Accord Says
• United, Next Health Denied Dismissals In $100M Fraud Suit
• GlaxoSmithKline Says FDA Rejected Zofran Birth Defects
• Health Hires: Wilson Sonsini, Ropes & Gray, Kirkland & Ellis
• PE-Backed UPL To Acquire Crop Solutions Biz For $4.2B
• What Directors Need To Include In Appraisal Notices
• Judge OKs $54M Aggrenox Settlement In Pay-For-Delay Suit
• The Opioid Epidemic: Who Will Jurors Hold Accountable?
• Fed. Circ. Says Tribal Immunity Doesn't Apply In IPR
• Suddenly, ALJs Become Political Appointees
• Hernia Mesh Maker Takes IP Suit Coverage Row To 3rd Circ.
• Genomic Cancer Testing Cos. Settle IPRs, Infringement Suit
• Cooley-Led Cannabis Co. Leads 5 IPOs Raising $446M
• Asbestos Link In $4.7B J&J Verdict Adds Twist To Talc Suits
• Medtronic Strikes $43M Deal To End Stock-Drop Suit
• Class Attorneys Secure $40M From Solodyn Pay-For-Delay
• ​​​​​​​Pharma Charity Likely Waived Free Speech Right, OIG Says
• Tendyne Investors Sue Abbott Over $50M Merger Bonus Miss
• Deals Rumor Mill: Fosun, UnitedHealth, Niu
• AngioDynamics Will Pay $12.5M To End DOJ's FCA Probe
• Genentech Drops Bid For White & Case Samsung Docs
• HHS Looks To Imports As Remedy For Drug Price Increases
• AbbVie Judge Rejects Interest Hike On AndroGel Penalty
• A Lawyer's Guide To Genomics In Toxic Tort Cases: Part 3
• PTAB Urged To Review CRISPR Gene-Editing Patent
• Cancer Pro To Monsanto Jury: Pesticide Study Critique 'Idiotic'
• Top Gov't Contracts Policy Changes So Far In 2018
• Goodwin-Led Biotech Tops 3 IPOs Totaling $384M
• No New Trial For 2 Convicted In Valeant Fraud
• Discovery In Opioid MDL Bellwethers Gets Big Haircut
• Opioid Distributors Can't Escape Counties' Suit
• Addiction Doesn't Keep Embezzling Union Rep Out Of Prison
• Deals Rumor Mill: IHeartMedia, Astellas, Aramco
• FDA Chief Blames Big Pharma For 'Anemic' Biosimilars Sales
• Jury Convicts Accountant Of Aiding Biotech VC In $18M Fraud
• A Chat With Gibson Dunn Diversity Chief Salim-Williams
• Mallinckrodt Looks To Exit Investor Suit Over Antitrust Deal
• A Lawyer's Guide To Genomics In Toxic Tort Cases: Part 2
• Congressional Forecast: July
• What Kavanaugh's Writing Tells Us About His Personality
• SEC Says Bio-Security Firm Owes It $19.7M In Fraud Case
• Employee Performance Ratings: Tainted Or Sainted?
• Federal Claims Court Says Drugmaker Can Sell Meds To VA
• Top Gov't Contracts Cases Of 2018 So Far
• EPA Official Tried To 'Kill' Pesticide Study, Monsanto Jury Told
• Drug Wholesalers Denied Class Cert. In AndroGel Suit
• Ex-Katten Atty Says Prison Unnecessary For Shkreli Fraud
• Product Liability Cases To Watch: Midyear Report
• DC Circ. Tosses Hospitals' Suit Over $1.6B Cut To 340B Pay
• FDA Warning Wire: 4 Splashy New Smackdowns
• 3 Pros, 3 Cons Of Litigation Finance
• A Lawyer's Guide To Genomics In Toxic Tort Cases: Part 1
• Engineering Co. Failed To Vet Plans, Builders Say In $13M Suit
• Ex-Drug Exec Gets 15 Years For $50M Pill Distribution Plot
• Allergan Awarded $27K In Sanctions In Compounding Suit
• RICO Indictment Against Ex-Insys Execs Perplexes Judge
• Praxair's New Twist On Subject Matter Ineligibility
• Diabetes Monitoring Co. Hits Ch. 11, Seeks Sale To Creditor
• Accountant Blames $18M Fraud On VC's Ego As Trial Wraps
• AbbVie Protests FTC Interest Hike In AndroGel Case
• Costco, Abbott Win Nutritional Drink Sales Tax Suit On Appeal
• Don't Rethink OK'ing Fanapt Patent, Vanda Tells Fed. Circ.
• Online Pharmaceuticals – But Not Much Online Liability
• OvaScience Investors Cannot Overtake Rival Class Action
• Wealth Manager Leads 4 IPO Launches Surpassing $1.1B
• Modern Communication Brings E-Discovery Challenges
• Federal Cannabis Legalization May Be Closer Than You Think
• Prepare For New Claim Construction Standard At PTAB
• Indivior Wins Bid To Block Sales Of Suboxone Generic
• Two Zeneca Defenses Nixed In $275M Chancery Drug Dispute
• EPA 'Amazingly Wrong' On Roundup Cancer Risk, Jury Hears
• Insulin Device Maker Settles Shareholder Derivative Suit
• Novartis Slams Sens.' Report About Michael Cohen Contract
• Fed. Circ. Upholds PTAB Ax Of 7 Xyrem Patents
• Bard Prevails In 3rd Bellwether Case Over Late Filing
• Spine Surgery Co. Says Competitor Claims Belong In Calif.
• 14 Firms To Guide IPOs Exceeding $1.1B As Deals Resume
• Fed. Circ. OKs Endo Win In Testosterone Therapy Patent Case
• NY Could Raise Up To $678M From Legal Pot, Report Says
• It's Not All About The Benjamins, Baby (Lawyer)
• FTC Wants To Keep Fighting Opana Pay-For-Delay Deal
• Shearman Works On $203M Alexandria-Pfizer Sale-Leaseback
• ACON Labs Cholesterol Strip IP Row Paused For ITC Probe
• Ortho's $19.5M Deal Ending Antitrust MDL Gets Initial OK
• Firm Wants Mesh MDL Fee Committee To Explain Hour Cuts
• Merck Beats Shareholder Row Over Tax Liability Disclosure
• Tax Implications For The California Cannabis Industry
• Novartis Beats PTAB Challenge To MS Drug Patent
• Mass. Biotech Company Closes $132M Series A Fundraising
• Judging A Book: Hood Reviews 'Lawyering From The Inside Out'
• Digital Health Opportunities And Considerations For PE
• Health Hires: King & Spalding, DLA Piper, Polsinelli, Quarles
• Acetris Case Clarifies Definition Of 'US-Made End Product'
• Monsanto's Roundup Tied To Cancer, Ex-NIH Official Testifies
• 1.6 Billion Opioid Doses Flooded Mo., McCaskill Says
• Chancery Nixes Most Of Suit Over $600M DAVA-Endo Merger
• Drug Wholesaler Not Covered For DEA Action Over Opioids
• Get Ready For Digital Health Product Liability Cases
• Insurers' New York Pfizer Coverage Suit Bites The Dust
• J&J Hit With $4.69B Verdict In 22-Woman Talc Cancer Trial
• J&J Says Talc-Cancer Link 'Fiction' At 22-Woman Trial's Close
• Kavanaugh Splurged On Baseball Tix, Reports Say
• IP Pros Urge High Court To Hear Inequitable Conduct Case
• FisherBroyles Adds Litigators in Florida, Philadelphia
• Merus Awarded $10.5M In Mouse Patent Fight
• 4 Kavanaugh Arguments You Gotta Hear
• DEA Finalizes Prescription Opioid Anti-Diversion Policy
• Kennedy's Legacy Remains Alive In Kavanaugh's Nomination
• Forbion's 4th Fund Hits 1st Close After Raising €270M
• Senate Panel Gearing Up For Kavanaugh Vetting Fight
• Otsuka Pharmaceutical Buys Mass. Biotech For $430M In Cash
• What Civil Rights Rulings Could Look Like Under Kavanaugh
• Rite Aid Booted, Walgreens Stuck In Suit Over Failed Merger
• Shire Gets $1M Less In Atty Fees Than Sought In Drug Win
• 3 Top E-Discovery Case Law Lessons Of 2018 (So Far)
• 'Not A Complicated Case': Kavanaugh's Straightforward Style
• Monsanto Discussed Downplaying Roundup Risks, Jury Hears
• Cosmo Hits Actavis With New Patent Suit Over Colitis Drug
• VC-Backed Biotech Co. Leads 2 IPO Launches Totaling $139M
• 'Shaky' Evidence Of Roundup-Cancer Link Admissible At Trial
• Dems Need Unified Front To Combat Trump's High Court Pick
• 5 Tips For Kavanaugh As Confirmation Gets Underway
• Wave Of FDA Suits Awaits If Kavanaugh Helps Trim Chevron
• Biomet Says It Needs Confidential Docs in Trade Secrets Row
• Highmark Nixed Health Plan To Drop Hemophiliacs, Suit Says
• With Kavanaugh's Nomination, Chevron's Future Looking Grim
• Cancer-Focused Vaccinex Joins IPO Party With $46M Offering
• Pfizer Gets Another Chance In Rituxan Patent Challenge
• Law Schools Must Take A Stand Against Mandatory Arbitration
• Atty Conflict Sinks Class Cert. Against Supplement Maker
• Biotech Co. Slams 'Rapacious Individuals' In $28M TM Suit
• Maine Court Strikes A Blow Against Medical Marijuana Users
• Ex-Akebia, Merrimack Analysts Found Guilty Of Insider Trades
• New Bill Addresses Systemic Risk In Cannabis Banking
• US Regulators Give Takeda Clearance For £46B Shire Deal
• How Kavanaugh's Conservative Cred, DC Ties Won The Day
• Senate Battle Lines Drawn With Kavanaugh As Trump's Pick
• Colgate Settles Baby Powder Cancer Claims On Eve Of Trial
• Pfizer, Insurer Venue Bids Denied In Coverage Fight
• Monsanto Fights Cancer Claims In 1st Roundup Jury Trial
• 5 Kavanaugh Opinions You Need To Read Right Now
• Trump Picks Brett Kavanaugh For Supreme Court
• DEA Doubles Down On Protecting Drug Info In Opioid MDL
• 9 IPO Launches Exceeding $1.2B Rev Up July Pipeline
• PTAB Will Review 2 Patents For Shire's ADHD Drug Mydayis
• Biotech Co. Didn't Disclose Rejected Patent, Investors Say
• Goodwin Steers $315M Abingworth Life Sciences Fund Close
• Atty's Claims Back Up Penalties In Biotech Fraud, SEC Says
• Ex-Akebia Employee Denies Trading On Drug Trial Results
• Ocular Looks To Kick Investor Suit Over Eye Drug Approval
• What You Need To Know For The Supreme Court Nomination
• FDA Releases Draft Guidance On Drug Indication Labeling
• Nevro Patents Likely Nixed From Row With Boston Scientific
• Colgate Dodges Discovery Sanctions In Benefits Dispute
• Fed. Circ. Backs Wright Medical's Patent Win On Surgical Tool
• Ill. Pharmacy Wins Class Cert. In TCPA Suit Over Drug Faxes
• Don't Wait For High Court, Reed Smith Widow Tells 7th Circ.
• Fed. Circ. OKs $14M For Gilead After Merck's Patent Lies
• 2nd Circ. Anthem, Express Scripts Pricing Row Rages On
• CVS Sued Over 'Memory-Enhancing' Dietary Supplement
• Myths And Facts About Using TAR Across Borders
• USTR Rolls Out Waiver Process For New China Tariffs
• The Lipitor MDL Court Did Its Job Correctly
• Turing, Shkreli Assail DQ Bid Targeting Fox Rothschild
• Halt Medical Resists US Trustee's Move To Convert Case
• Prothena Hit With Stock-Drop Suit After Failed Clinical Trials
• Osco Drug Wants Sanctions In Prescription Refill TCPA Suit
• French Biotech Nabs €47M In Andera-Led Funding Round
• Vaccine Mandates And Lessons On Legal Compliance
• Drug Cos. Assail Hospital Bellwether In Opioid MDL
• Merck Patent Case Supports Use Of 'Unclean Hands' Defense
• Trump's China Tariffs Take Hold As Biz Groups Sound Alarm
• Atty Pushes To Arbitrate Legal Malpractice Suit
• J&J Expert Says Talc Plaintiffs Had Other Cancer Causes
• Baxter, Hospira Freed From Saline Price-Fixing Case For Now
• Genentech Sues Eli Lilly For Violating Just-Issued Drug Patent
• Bristol-Myers, Otsuka Beat Suit Over Abilify Side Effects
• Insider-Trading Suspect Says He Lied To Friend, Not Feds
• Pa. Justices To Mull Risperdal Breast-Growth Time Limit
• Deals Rumor Mill: Bristol-Myers Squibb, Aramco, Abraaj
• $140M Verdict Against AbbVie In Testosterone MDL Tossed
• MSN, Sandoz Settle Sunovion's IP Suit Over Latuda Generics
• Heart Meds Recalled In UK, EU, For Possible Cancer Link
• Baker Donelson Blasts DQ Bid In BCBS Antitrust Row
• The Top Patent Cases Of 2018: Midyear Report
• Law360 Reveals The Global 20 Firms Of 2018
• How Smaller Firms Can Go Global Without Going Bankrupt
• Global Law Firms Bulk Up In Europe As Brexit Approaches
• Direct Drug Purchasers Aim For Consolidation In Zetia MDL
• Some Good Prop 65 News For Businesses
• Feds Rework 'Misleading' Key Data For Insider-Trading Trial
• FDA Warning Wire: Pfizer Promo Video Eyed
• Three Firms Guide Catalent's $140M Pharma Biz Buy
• What The AbbVie Decision Says About Sham Patent Cases
• Medical Pot Smoking Ban Stays In Place As Fla. Fights On
• Chinese BioPharma Co. Lands $86.73M Private Placement
• Drug Wholesalers Ask For Cert. Over Lamictal Generic Delay
• Boston Scientific Can't Toss 800 Pelvic Mesh Suits
• From Lawmaker To Lawyer
• Lexion Gets SurgiQuest 'Tube' Patent Axed By PTAB
• The Sharpest Dissents From The Supreme Court Term
• High Court Nomination Watch: 7th Circ.'s Amy Coney Barrett
• Narrow Rulings Reveal Wide Gulfs Between Justices
• 4 High Court Lineups That Might Surprise You
• The Funniest Moments Of The Supreme Court Term
• Abbott Must Look Again For Docs Sought By Alere Investors
• Mitsui Stole Trade Secrets And Broke NDA, Florida Co. Says
• 23andMe DNA Patent Invalid Under Mayo, Ancestry.com Says
• Trump Plows Ahead With Supreme Court Selection Process
• Drug Cos. In Opioid MDL Must Divulge Vast Data Trove
• CVS Wants Antitrust Suit Over 340B Drug Program Tossed
• Fed. Circ. Upholds Rejection Of Artificial Glands Patent
• New Support For Insureds Facing Government Subpoenas
• Pa. Court Axes 2nd Challenge To Medical Marijuana Licenses
• A Trump Supreme Court Nominee Can Be Defeated
• The Most Talkative Justices Of The Term
• The Firms That Won Big At The Supreme Court
• The Supreme Court Term By The Numbers